Idarubicin

Generic Name: Idarubicin

Brand Names: Idamycin

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₂₇NO_₉

CAS Number: 58957-92-9

Unique Ingredient Identifier: ZRP63D75JW

Background: An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

Indication: For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.

Associated Conditions: Acute Myeloid Leukemia

Associated Therapies: -

Clinical Trials

Efficacy of G-CSF-Priming in Elderly AML Patients

Phase 4

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-09-20

Last Posted Date: 2005-10-26

Lead Sponsor: Johann Wolfgang Goethe University Hospital

Target Recruit Count: 250

Registration Number: NCT00199147

Locations: 🇩🇪
University Hospital, Medical Department II, Frankfurt, Germany

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

First Posted Date: 2005-09-20

Last Posted Date: 2022-08-18

Lead Sponsor: Goethe University

Target Recruit Count: 1883

Registration Number: NCT00198991

Locations: 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany

German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Adult Acute Lymphocytic Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Dexamethasone / Prednisolone
Drug: Cytarabine
Drug: Idarubicin
Drug: Granulocyte-Colony-Stimulating Factor
Drug: Mercaptopurine
Drug: Methotrexate
Drug: Rituximab
Drug: HDARAC
Drug: Vincristine
Drug: Depocyte
Drug: Asparaginase

First Posted Date: 2005-09-20

Last Posted Date: 2023-03-20

Lead Sponsor: Goethe University

Target Recruit Count: 377

Registration Number: NCT00198978

Locations: 🇩🇪
University of Frankfurt, Medical Dept. II, Frankfurt, Germany

Study Comparing Imatinib With Chemotherapy as Induction in Elderly Patients With Philadelphia Positive Acute Lymphoblastic Leukemia (ALL)

Phase 2

Conditions: Philadelphia Positive Acute Lymphoblastic Leukemia
Lymphoid Blastic Phase of Chronic Myeloid Leukemia

First Posted Date: 2005-09-20

Last Posted Date: 2007-10-19

Lead Sponsor: Johann Wolfgang Goethe University Hospital

Registration Number: NCT00199186

Locations: 🇩🇪
Medizinische Klinik II, Johann Wolfgang Goethe Universität, Frankfurt/Main, Germany

Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia

Phase 4

Completed

Conditions: Adult Acute Lymphocytic Leukemia

First Posted Date: 2005-09-20

Last Posted Date: 2023-03-20

Lead Sponsor: Goethe University

Target Recruit Count: 40

Registration Number: NCT00199095

Locations: 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany

German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (06/99)

Phase 4

Completed

Conditions: Adult Acute Lymphocytic Leukemia

First Posted Date: 2005-09-20

Last Posted Date: 2023-03-20

Lead Sponsor: Goethe University

Target Recruit Count: 225

Registration Number: NCT00199056

Locations: 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany

AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia

Phase 4

Conditions: Leukemia, Promyelocytic, Acute

First Posted Date: 2005-09-16

Last Posted Date: 2011-07-11

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 80

Registration Number: NCT00180128

Locations: 🇩🇪
Department of Medicine I, University Hospital Carl Gustav Carus, Dresden, Germany

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cytarabine
Drug: Idarubicin
Drug: Etoposide
Drug: All-trans retinoic acid
Drug: Pegfilgrastim

First Posted Date: 2005-09-08

Last Posted Date: 2017-09-20

Lead Sponsor: University of Ulm

Target Recruit Count: 920

Registration Number: NCT00151242

Locations: 🇩🇪
Clinical Center of Hematology and Oncology, University Hospital of Düsseldorf, Düsseldorf, Germany
🇦🇹
Department of Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria
🇩🇪
Department of Hematology and Oncology, Hospital Essen Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 31 locations

All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-09-08

Last Posted Date: 2017-04-19

Lead Sponsor: University of Ulm

Target Recruit Count: 500

Registration Number: NCT00151255

Locations: 🇦🇹
Department of Internal Medicine I, Krankenhaus der Barmherzigen Schwestern, Linz, Austria
🇩🇪
Medical Department I, Hospital of Bremen-Mitte, Bremen, Germany
🇩🇪
Department of Hematology and Oncology, Hospital Essen-Süd, Ev. Hospital of Essen-Werden, Essen, Germany

and more 26 locations

Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result

Phase 3

Completed

Conditions: Acute Myeloid Leukemia

First Posted Date: 2005-09-05

Last Posted Date: 2009-02-09

Lead Sponsor: University of Ulm

Target Recruit Count: 400

Registration Number: NCT00146120

Locations: 🇩🇪
I. Medical Department, City Hospital München-Schwabing, München, Germany
🇩🇪
Centre of Interial Medicine, University of Göttingen, Göttingen, Germany
🇩🇪
Medical Department III of Hematology and Oncology, General Hospital Altona, Hamburg, Germany

and more 19 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy